Journal of Antimicrobial Chemotherapy (2000) 46, 931-940
© 2000 The British Society for Antimicrobial Chemotherapy
Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid
a Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, Colindale Avenue, London NW9 5HT; b Pharmacia Corporation, Davy Avenue, Knowlhill, Milton Keynes MK5 8PH, UK
The prevalence of antibiotic resistance amongst Gram-positive cocci from 25 UK hospitals was studied over an 8 month period in 1999. A total of 3770 isolates were tested by the sentinel laboratories using the Etest; these bacteria comprised 1000 pneumococci, 1005 Staphylococcus aureus, 769 coagulase-negative staphylococci (CNS) and 996 enterococci. To ensure quality, 10% of the isolates were retested centrally, as were any found to express unusual resistance patterns. The prevalence of penicillin-resistant Streptococcus pneumoniae, vancomycin-resistant enterococci and methicillin-resistant S. aureus (MRSA) varied widely amongst the sentinel laboratories. The resistance rates to methicillin among S. aureus and CNS were 19.2 and 38.9%, respectively, with MRSA rates in individual sentinel sites ranging from 0 to 43%. No glycopeptide resistance was seen in S. aureus, but 6.5% of CNS isolates were teicoplanin resistant and 0.5% were vancomycin resistant. Vancomycin resistance was much more frequent among Enterococcus faecium (24.1%) than E. faecalis (0.5%) (P < 0.05), with most resistant isolates carrying vanA. The rate of penicillin resistance in pneumococci was 8.9%, and this resistance was predominantly intermediate (7.9%), with only six hospitals reporting isolates with high level resistance. The prevalence of erythromycin resistance among pneumococci was 12.3%, with the majority of resistant isolates having the macrolide efflux mechanism mediated by mefE. All the organisms tested were susceptible to linezolid with MICs in the range 0.12–4 mg/L. The modal MICs of linezolid were 1 mg/L for CNS and pneumococci, and 2 mg/L for S. aureus and enterococci. Linezolid was the most potent agent tested against Gram-positive cocci, including multiresistant strains, and as such may prove a valuable therapeutic option for the management of Gram-positive infections in hospitals.
* Corresponding author. Tel: +44-20-8200-4400, ext. 4282; Fax: +44-20-8358-3292; E-mail: chenwood{at}phls.nhs.uk
Deceased; this paper is dedicated to his memory.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. N. Jones, J. E. Ross, T. R. Fritsche, and H. S. Sader Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations J. Antimicrob. Chemother., February 1, 2006; 57(2): 279 - 287. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Lin, K. Smith, L. M. Ednie, and P. C. Appelbaum Antipneumococcal Activity of Dalbavancin Compared to Other Agents Antimicrob. Agents Chemother., December 1, 2005; 49(12): 5182 - 5184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bogdanovich, L. M. Ednie, S. Shapiro, and P. C. Appelbaum Antistaphylococcal Activity of Ceftobiprole, a New Broad-Spectrum Cephalosporin Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4210 - 4219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Johnson, A. Pearson, and G. Duckworth Surveillance and epidemiology of MRSA bacteraemia in the UK J. Antimicrob. Chemother., September 1, 2005; 56(3): 455 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bogdanovich, D. Esel, L. M. Kelly, B. Bozdogan, K. Credito, G. Lin, K. Smith, L. M. Ednie, D. B. Hoellman, and P. C. Appelbaum Antistaphylococcal Activity of DX-619, a New Des-F(6)-Quinolone, Compared to Those of Other Agents Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3325 - 3333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Ziglam, I. Elliott, V. Wilson, K. Hill, and D. Nathwani Clinical audit of linezolid use in a large teaching hospital J. Antimicrob. Chemother., August 1, 2005; 56(2): 423 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lin, K. Credito, L. M. Ednie, and P. C. Appelbaum Antistaphylococcal Activity of Dalbavancin, an Experimental Glycopeptide Antimicrob. Agents Chemother., February 1, 2005; 49(2): 770 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Ednie, G. Pankuch, and P. C. Appelbaum Antipneumococcal Activity of LBM415, a New Peptide Diformylase Inhibitor, Compared with Those of Other Agents Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4027 - 4032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Credito, G. Lin, L. M. Ednie, and P. C. Appelbaum Antistaphylococcal Activity of LBM415, a New Peptide Deformylase Inhibitor, Compared with Those of Other Agents Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4033 - 4036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Hoellman, G. A. Pankuch, and P. C. Appelbaum Antistaphylococcal Activity of CB-181963 (CAB-175), an Experimental Parenteral Cephalosporin Antimicrob. Agents Chemother., October 1, 2004; 48(10): 4037 - 4039. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Brown and B. B Freeman III Combining Quinupristin/Dalfopristin with Other Agents for Resistant Infections Ann. Pharmacother., April 1, 2004; 38(4): 677 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Cepeda, T. Whitehouse, B. Cooper, J. Hails, K. Jones, F. Kwaku, L. Taylor, S. Hayman, S. Shaw, C. Kibbler, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study J. Antimicrob. Chemother., February 1, 2004; 53(2): 345 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Smith, M. C. Birmingham, G. A. Noskin, A. K. Meagher, A. Forrest, C. R. Rayner, and J. J. Schentag Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia Ann. Onc., May 1, 2003; 14(5): 795 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Novais, J. C. Sousa, T. M. Coque, L. V. Peixe, and the Resistance Study Group First report of the activity of linezolid against Portuguese enterococci from human, animal and environmental sources J. Antimicrob. Chemother., May 1, 2003; 51(5): 1314 - 1315. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Hoellman, G. Lin, L. M. Ednie, A. Rattan, M. R. Jacobs, and P. C. Appelbaum Antipneumococcal and Antistaphylococcal Activities of Ranbezolid (RBX 7644), a New Oxazolidinone, Compared to Those of Other Agents Antimicrob. Agents Chemother., March 1, 2003; 47(3): 1148 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bell, J. D. Turnidge, C. H. Ballow, R. N. Jones, and the ZAPS Regional Participants Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific J. Antimicrob. Chemother., February 1, 2003; 51(2): 339 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Pankuch, M. R. Jacobs, and P. C. Appelbaum Bactericidal activity of daptomycin against Streptococcus pneumoniae compared with eight other antimicrobials J. Antimicrob. Chemother., February 1, 2003; 51(2): 443 - 446. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Moellering Jr. Linezolid: The First Oxazolidinone Antimicrobial Ann Intern Med, January 21, 2003; 138(2): 135 - 142. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Arias, J. Reyes, M. Zuniga, L. Cortes, C. Cruz, C. L. Rico, D. Panesso, and on behalf of the Colombian Antimicrobial Resistanc Multicentre surveillance of antimicrobial resistance in enterococci and staphylococci from Colombian hospitals, 2001-2002 J. Antimicrob. Chemother., January 1, 2003; 51(1): 59 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Johnson, M. Warner, J. S. Nguyen-Van-Tam, and D. M. Livermore Activity of gemifloxacin against invasive and multi-resistant Streptococcus pneumoniae isolates collected in the UK J. Antimicrob. Chemother., January 1, 2003; 51(1): 188 - 190. [Full Text] [PDF]
|
|
|
|
|
|
T. R. Anderegg, D. J. Biedenbach, and R. N. Jones In Vitro Evaluation of AZD2563, a Novel Oxazolidinone, against 603 Recent Staphylococcal Isolates Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2662 - 2664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Johnson, M. Warner, and D. M. Livermore In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci J. Antimicrob. Chemother., July 1, 2002; 50(1): 89 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peric, G. Lin, C. L. Clark, M. R. Jacobs, and P. C. Appelbaum Antipneumococcal activity of AZD2563, a new oxazolidinone, compared with nine other agents J. Antimicrob. Chemother., July 1, 2002; 50(1): 95 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Srinivasan, J. D. Dick, and T. M. Perl Vancomycin Resistance in Staphylococci Clin. Microbiol. Rev., July 1, 2002; 15(3): 430 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. E. Konstantinov and K. J. Zehr Aortic Root Replacement in a Patient With Vancomycin-Resistant Enterococcus faecium Endocarditis and Leukemia Chest, November 1, 2001; 120(5): 1744 - 1746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Henwood, M. Warner, P. Waight, A. P. Johnson, R. C. George, and D. M. Livermore Accuracy of routine susceptibility testing of Streptococcus pneumoniae in England and Wales J. Antimicrob. Chemother., June 1, 2001; 47(6): 897 - 900. [Full Text] [PDF]
|
|
|
|
|
|
A. P. Johnson, M. Warner, R. C. George, and D. M. Livermore Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales J. Antimicrob. Chemother., April 1, 2001; 47(4): 411 - 415. [Abstract] [Full Text] [PDF]
|
|